Following the success of blinatumomab, a CD19-targeted bispecific antibody for the treatment of acute lymphoblastic leukemia, clinical trials have investigated CD33-targeted bispecific antibodies for AML. This evidence concerns the gene CD33 and acute lymphoblastic leukemia.